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Abstract  
Rationale:  Dehydroepiandrosterone (DHEA) has been reported to enhance cognition in rodents though 
there are inconsistent findings in humans.  Objectives: The aim of this study was to investigate the 
effects of DHEA administration in healthy young men on episodic memory and its neural correlates 
utilising an event-related potential (ERP) technique.   Methods: 24 healthy young men were treated 
with a 7-day course of oral DHEA (150mg b.d) or placebo in a double blind, random, crossover and 
balanced order design.  Subjective mood and memory were measured using visual analogue scales 
(VASs).  Cortisol concentrations were measured in saliva samples.  ERPs were recorded during 
retrieval in an episodic memory test.  Low-resolution brain electromagnetic tomography (LORETA) 
was used to identify brain regions involved in the cognitive task.  Results: DHEA administration lead 
to a reduction in evening cortisol concentrations and improved VAS mood and memory.  Recollection 
accuracy in the episodic memory test was significantly improved following DHEA administration.  
LORETA revealed significant hippocampal activation associated with successful episodic memory 
retrieval following placebo.  DHEA modified ERPs associated with retrieval and led to a trend towards 
an early differential activation of the anterior cingulate cortex (ACC).   Conclusions: DHEA treatment 
improved memory recollection and mood and decreased trough cortisol levels.  The effect of DHEA 
appears to be via neuronal recruitment of the steroid sensitive ACC that may be involved in pre-
hippocampal memory processing. These findings are distinctive, being the first to show such beneficial 
effects of DHEA on memory in healthy young men.   
 
Keywords DHEA, Cortisol, Episodic Memory, Recognition, Mood, Event-Related 
Potentials (ERPs), Low-Resolution Brain Electromagnetic Tomography (LORETA).  
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Introduction 
Dehydroepiandrosterone (DHEA) is a steroid produced in the zona reticularis of the 
adrenal glands and also independently in the brain (Baulieu 1997; Majewska et al. 
1990).  The sulphated form, DHEA-S is the most abundant steroid in plasma and 
cerebrospinal fluid (CSF) in humans (Wolf and Kirschbaum 1999).  DHEA may be 
involved in the pathophysiology of the cognitive decline with age and mood 
disorders.  
  
During adulthood, DHEA concentrations decrease dramatically with age so that at age 
80 are they are about one fifth of those at age 20 (Orentreich et al. 1984; Gray et al. 
1991).  This decline has been postulated as a possible explanation of many age-related 
illnesses including memory impairment (Baulieu et al. 2000).  Some studies in 
patients with Alzheimer’s disease have shown a significant correlation between 
cognitive impairment and low plasma concentrations of DHEA-S compared with 
controls (Nasman et al. 1991; Yanase et al. 1996), though a number of other studies 
have found no such difference between patients with Alzheimer's disease and healthy 
controls (Leblhuber et al. 1993; Carlson et al. 1999).  An inverse correlation between 
DHEA concentrations and cognition has been also shown in elderly females (Breuer 
et al. 2001).  However, other studies have failed to reveal any significant correlation 
between DHEA and/or DHEA-S and the age-related decline in cognition (Barrett-
Connor and Edelstein 1994; Moffat et al. 2000).  
 
Administration of DHEA has been suggested as a possible neuro-protective 
intervention that may impede decline in memory and cognitive function in normal 
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ageing and dementia (Bologa et al. 1987; Nasman et al. 1991).  Indeed, many rodent 
and other animal studies have demonstrated that DHEA administration enhances 
memory performance in healthy young (Flood et al. 1988; Migues et al. 2002), as well 
as in ageing and cognitively impaired animals (Flood and Roberts 1988; Shi et al. 
2000).  However, the extrapolation of such findings in animals to humans is 
problematic since DHEA concentrations in rodents are significantly lower than in 
man (Vallee et al. 2001).  Further, in humans results have been inconsistent and 
almost all placebo-controlled trials have found no beneficial effects on memory in 
healthy old subjects (Barnhart et al. 1999; Wolf et al. 1997; Wolf et al. 1998; van 
Niekerk et al. 2001) or patients with Alzheimer's disease (Wolkowitz et al. 2003).  
This could be due to the use of different dosage, variation of period of DHEA 
administration and age of subjects.  
 
It is well documented that the Hypothalamic Pituitary Adrenal (HPA) axis is 
dysfunctional in depression (McAllister-Williams et al. 1998).  Abnormally high 
cortisol concentration is a frequent, though not consistent finding, in depressed 
patients (Dinan 1994; Arborelius et al. 1999).  DHEA has also been implicated in the 
pathophysiology of depressive illness.  DHEA and DHEA-S have been demonstrated 
to be inversely correlated with depressive mood (Barrett-Connor et al. 1999) and 
DHEA administration has been shown to improve mood in patients with depression 
(Wolkowitz et al. 1999), though there has been a report of elevated DHEA in major 
depression (Heuser et al. 1998).  This effect could relate to DHEA acting as a 
functional cortisol antagonist (Browne et al. 1992; Kalimi et al. 1994), including 
counteracting the deleterious effects of corticosteroids on neuropsychological function 
in rodents (Kaminska et al. 2000).  It has been argued that the functional 
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hypercortisolaemia seen in depression is best assessed by measuring Cortisol/DHEA 
ratio (Goodyer et al. 1998), which is found to be increased in cognitively impaired 
drug-free depressed patients compared to healthy controls (Young et al. 2002).   
 
Cortisol administration to healthy subjects produces cognitive impairments similar to 
those seen in depression (Newcomer et al. 1999; de Quervain et al. 2000).  In a recent 
study repeated administration of cortisol to healthy young men led to an impairment 
in recognition accuracy associated with alterations in the neural correlates of episodic 
memory retrieval, as assessed using an event-related potential (ERP) technique 
(McAllister-Williams and Rugg 2002).   
 
The aim of the current study was to investigate the effect of repeated DHEA 
administration in a group of healthy young men on salivary cortisol concentrations 
and mood as well as exploring effects on the neural correlates of episodic memory 
retrieval using an identified ERP technique to that used to explore the effects of the 
repeated cortisol administration (McAllister-Williams and Rugg 2002).  To detect 
brain regions activated during the cognitive task, low-resolution brain electromagnetic 
tomography (LORETA) was used (Pascual-Marqui et al. 1994; Pascual-Marqui et al. 
1999).  We hypothesised that DHEA would decrease cortisol concentrations, improve 
memory and lead to qualitative alterations in neuronal activity related to episodic 
memory retrieval.  
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Material and Methods  
Subjects 
The study population consisted of 24 healthy male volunteers aged between 18 and 
40, recruited by advertisement from the local population.  All were right-handed as 
assessed using Briggs’ modification of Annett’s (1967) handedness inventory (Briggs 
and Nebes 1975).   The inclusion criteria required that subjects had an IQ of ninety or 
more as assessed by the National Adult Reading Test (NART) and be fluent in 
English in order to be familiar with all the words used in the experiment.  Subjects 
were excluded if they had any significant past or current medical history, or any 
personal or first-degree family history of psychiatric illness.  Baseline mood was 
assessed using the Beck Depression Inventory (BDI) (Beck et al. 1961) and subjects 
were not included if they scored 8 or more.  They were required not to be taking any 
medication with the exception of Paracetamol (Acetaminophen).  Subjects provided 
written informed consent prior to participation and they were reimbursed for their 
time and expenses.  Ethical approval was obtained from the Newcastle and North 
Tyneside Local Research Ethics Committee.  
 
Experimental Design 
A double-blind placebo-controlled crossover design was used.  
Electroencephalographic (EEG) recordings were made from each subject during two 
separate visits following a seven-day course of 150 mg DHEA, or placebo, twice 
daily (i.e. a total daily dose of 300 mg).  The treatments were administered in a 
random, balanced, order, with at least a four-week interval between treatment periods 
in order to exclude any carry-over effects of DHEA and minimise the learning effect 
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of the memory test.  Subjects were asked to record the time they took medication and 
the duration and quality of sleep in a logbook.   
 
Participants attended the Department of Psychiatry, the Royal Victoria Infirmary 
(RVI), Newcastle upon Tyne at 08:50 h.  They were given breakfast and decaffeinated 
tea or coffee.  The last dose of treatment was administered at 09:00 h, followed by the 
placement of an electrode cap on the scalp for EEG recordings.  Visual analogue scale 
(VAS) measures were administered and the subjects were requested to report any 
adverse and/or beneficial effect of treatment they may have noticed during the last 
week.  The purpose of the experiment and the instructions were explained to the 
subjects thoroughly.  
 
DHEA and Cortisol Assay 
Four saliva samples were collected 1 day prior to each visit at 1200, 1600, 2100 (just 
before the evening dose of medication) and 2200h. A further five saliva samples were 
collected on the day of testing at 0900 (baseline before last dose of medication), 0930, 
1000, 1100 and 1230 h. Samples were collected by passive drooling (spitting into a 
plastic tube), without using aids to salivation or swabs.  Cortisol and DHEA 
concentrations in the saliva samples were assayed using a coated tube radio-
immunoassay (RIA) kit obtained from M P Biomedicals (Tyne & Wear, UK).  Intra-
assay variations for cortisol and DHEA were 6.2% and 8.3%, and inter-assay 
variations 3.0% and 4.2%, respectively.   
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Visual Analogue Scale (VAS) 
Visual analogue scales (VASs) were used to assess subjective feelings of mood, well-
being, memory, sexual drive, appetite and alertness.  The VAS measures consisted of 
a 10 cm bar with “best” and “worst” indicated at its extremities for each variable.   
 
Experimental Items for ERP Procedure  
These were identical to material employed in previous studies (Wilding and Rugg 
1996; McAllister-Williams and Rugg 2002).  In brief, stimuli consisted of low 
frequency (1-7 per million) words selected from Kucera and Francis corpus (1967).  
In the study phase subjects were presented with two lists of word presented 
binaurally.  In each word list, half of the words were spoken in a male voice and half 
in a female voice randomly determined.  Associated test lists were created with 50% 
old words presented in the study lists and 50% new words.  Test lists of words were 
presented visually on a computer monitor, with each word presented for 500 ms and 
subtending a vertical angle of 0.5º and a maximum horizontal angle of 2.8º.  Subjects 
were exposed to two different study/test lists on each of the two recording sessions.  
 
Episodic Memory Task 
Subjects were informed that the aim of the experiment was to investigate memory for 
spoken words.  On each of two visits subjects underwent an orientation and 
preliminary practice session utilising study and test words not included in the actual 
experiment.  Following the practice, subjects undertook two study/test cycles, as 
described above.  
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As in previous investigations (Wilding and Rugg 1996; McAllister-Williams and 
Rugg 2002), the voice in which each study item was presented dictated which of two 
encoding tasks should be performed.  Subjects were instructed to listen to each word 
and to respond verbally by repeating the word aloud and then judge whether it was 
active/passive or pleasant/unpleasant.  This procedure was performed to enhance the 
encoding process.  The mapping of task to gender was counterbalanced across 
subjects.   
 
The study phase was followed by a period of 15 minutes rest, during which the 
subject’s attention was distracted and then the test phase was conducted.  First, an 
asterisk appeared on the screen for one second as a fixation point and to advise the 
subject that they were about to see the stimulus word.  Then a word was presented and 
the subject was asked to respond as quickly and accurately as possible as to whether 
this was an old word they had heard during the study phase or a new one, using the 
thumb of either their left or right hand.  A question mark appeared on the screen 
following the subject’s response for 2.5 seconds and they were instructed that when 
they saw if the word was old they should indicate the gender of the voice that spoke 
the word and respond by pressing one of the two buttons.  No response was required 
if the word was new.  For each subject, the same evaluation of the voice 
(pleasant/unpleasant or active/passive) and the same button assignment (old/new, 
male/female) remained consistent in both visits to avoid any possible confusion.  
These voice and button assignments were counterbalanced across subjects to ensure 
that there was no correlation between the hands used for old/new and male/female 
judgement.  The total time including orientation/practice study-test block and two 
experimental study-test blocks was approximately 75 min.   
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ERP Recording 
EEG was recorded using an elasticated cap (Easy Caps, Germany) with 29 
silver/silver chloride electrodes placed on the scalp in accordance with the 
International 10-20 system (American Electroencephalographic Society 1994).  Two 
additional electrodes were placed on mastoid processes, with the left mastoid 
electrode as a reference to all channels and ERPs were algebraically reconstructed off-
line to represent recordings with respect to an average mastoid reference.  Vertical 
EOG was recorded between electrodes placed below each eye and an electrode placed 
on the nasion.  Horizontal EOG was recorded between electrodes placed on the outer 
canthus of the left and right eyes.  EEG and EOG were filtered with a bandpass of 
0.01-100 Hz and sampled at a rate of 6 ms per point for an epoch of 1536 ms 
beginning 102 ms before the onset of words presented in the test phase.  
 
Average ERPs were generated for each subject for recognised old words attracting 
correct source judgements, and for correctly identified new items.   To maximise the 
number of trials available for averaging, a blink-correction procedure was employed 
utilizing vertical EOG recordings.  Any trial containing residual artefact was rejected 
if any channel, except VEOG, had a voltage deflection greater than ±75µV.  To 
maintain an acceptable signal/noise ratio, a lower limit of 20 artefact-free trials per 
subject per visit per response category was set.  
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Source Localisation of the Electric Activity 
LORETA, a source localisation technique was used to estimate the three-dimensional 
intracerebral current density distribution from the scalp electric potential differences 
(Pascual-Marqui et al. 1994; Pascual-Marqui et al. 1999).  In this method, the cortex 
is modelled as 2394 voxels using the digitized Talairach atlas (Talairach J and 
Tournoux P 1988), with a spatial resolution of 0.343 cm3 (Pascual-Marqui et al. 
1999).  LORETA depends on a smoothness assumption according to which 
neighboring neuronal populations show highly correlated activity, thus solving the 
non-unique ‘inverse’ problem that results from the calculation of the electric sources 
from potentials recorded on the scalp surface (Pascual-Marqui et al. 1999).  The 
resulting solution has relatively low spatial resolution, preserving the location of 
maximal activation but with some dispersion.  In recent years, accumulating literature 
has shown LORETA localisation to be consistent with functional magnetic resonance 
imaging (fMRI) results (Seeck et al. 1998).  However, the validity of LORETA 
solutions, particularly localisation of small and deep electrical generators, such as the 
hippocampus has been questioned (Grave de Peralta Menendez et al. 2000; Phillips et 
al. 2002; Fontanarosa et al. 2004).  As a consequence, the results of LORETA in this 
study were treated with caution and simply an adjunct to topographical analysis of the 
ERP data. 
 
Statistical Analysis 
All values are quoted as means ± standard deviations.   Statistical comparisons were 
made using analysis of variance (ANOVA) incorporating the Geisser-Greenhouse 
correction for inhomogeneity of covariance.  F ratios are reported with corrected 
degrees of freedom.  Statistical significance was adjudged at the p<0.05 level.   
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LORETA software (LORETA-KEY version June 2003; The Key Institute for Brain–
Mind Research, Switzerland) was used to perform statistical non-parametric mapping 
(Pascual-Marqui et al. 1994; Pascual-Marqui et al. 1999).  To identify time periods of 
statistical difference between ERP scalp maps associated with different conditions, 
topographic analysis of variance (TANOVA) was conducted to calculate the 
probability of dissimilarity for each response at 6 ms intervals from -102 to 1434 ms 
relative to stimulus presentation.  This procedure is a non-parametric randomisation 
test computing statistical significance for each pair of maps, correcting for multiple 
comparison (Thomas and Holmes 2002).  Following identification of the statistically 
significant differences in scalp activity by TANOVA, LORETA was utilised to 
identify underlying neural generators during the same time period.  A LORETA 
image was generated within the significant time period for each cortical voxel.  
Statistical non-parametric paired t-tests were performed for the comparison of current 
density distribution between conditions on a voxel-by-voxel basis, corrected for 
multiple testing. 
 
Results  
Subjects’ mean age was 23.6±5.1 years (range 18-34) and their IQ was 109.8±6.7 
(range 100-123).  Subjects had no mood complaint with a BDI of 1.7±1.5 (range 0-5).  
Nineteen out of twenty-four subjects were non-smokers, while the other five smoked 
less than six cigarettes per day.   
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Salivary DHEA and Cortisol Concentrations  
The average salivary concentrations of DHEA following active treatment and placebo 
were 1450.5±979.1 pg/ml and 691.4±474.3 pg/ml, respectively.  ANOVA 
incorporated all nine saliva samples revealed a significant treatment effect (F(18, 1)= 
36.7; p<0.0001) (see Fig 1a).  There was also a significant effect of time (F(71.4, 
4.0)=2.5; p<0.05);  however no significant drug-by-time interaction was found 
(p>0.1).   
 
Salivary cortisol concentrations showed the expected diurnal rhythm with placebo 
administration (see figure 1b).  Overall salivary cortisol concentrations were not 
significantly different following DHEA administration (F(18,1)=0.14; p>0.1).  
However, post-hoc exploration of the data using paired t-tests suggested that DHEA 
led to a reduction in evening cortisol concentrations (2100 and 2200 h. samples) 
compared to placebo (1.6mmole/l vs 3.2mmole/l p<0.05 and 0.8mmole/l vs 
2.1mmole/l p<0.1 respectively; see figure 1b).  
 
DHEA Tolerability, Effects on Sleep and Subjective Ratings 
DHEA was well tolerated and there was no significant difference between side effects 
of DHEA and placebo treatments.  There was no difference in either sleep duration 
(7.2±1.07 vs. 7.3±1.05 hours) or quality ratings (64.5±15 vs. 65.7±14.6) between the 
week that DHEA and placebo were administered respectively.    
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VASs were only available for 16 subjects.  DHEA administration significantly 
improved subjective mood (t(15)= -2.5, p<0.05) and memory (t(15)= -2.1 p< 0.05)  
but had no effect on the other VAS measures (see table1). 
 
Episodic Memory Performance  
A previous study using identical study and test stimuli found no significant effect of 
the sex of the voice on response accuracy or speed (Wilding and Rugg 1996).   
Consequently all behavioural analysis was performed on data collapsed across gender 
of voice speaking the items at study.   In line with previous studies (Wilding and 
Rugg 1996; McAllister-Williams and Rugg 2002), trials in which words were 
correctly judged new will be referred to as ‘correct rejections’ (CR), and new words 
judged to be old as ‘false alarms’ (FA).   Trials on which words were correctly judged 
to be ‘old’ are referred to as ‘hits’ (H), and if correctly assigned to their study context 
as ‘hit/hits’ (HH).   Analysis of the behavioural data focused on two measures: 
recognition, as assessed by the discrimination index (pH - pFA) (Snodgrass and 
Corwin 1988), and recollection, as indicated by the probability of correct study 
context judgement given recognition (pHH/pH).   
 
ANOVA employed a within subject factor of drug (DHEA vs. placebo) and a 
between-subject factor of the visit the drug was administered (first vs. second). There 
was no significant effect of visit on either recognition or recollection, indicating no 
learning effect.  There was no significant effect of DHEA treatment on recognition 
(p>0.1; figure 2a), though there was a significant effect on recollection (p<0.01) 
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(figure 2b), reflecting a general improvement in performance following DHEA 
administration compared with placebo.  
 
ERP and LORETA Analysis 
In line with previous studies, only ERPs associated with CR and HH responses were 
analysed.   Other types of responses occurred at too low a frequency to provide 
sufficient numbers of trials to generate reliable average ERP waveforms.   Previous 
work using the same stimuli found no effect of the gender of the study voice on the 
ERP wave forms (in line with a lack of effect on the behavioural responses; (Wilding 
and Rugg 1996) and so ERPs were collapsed across study voice.   
 
Four subjects were excluded from ERP analysis due to poor quality EEG recordings 
with movement artefacts that could not be corrected.   Grand averages of the ERPs for 
the HH and CR response categories from the 20 subjects following treatment with 
placebo are illustrated in figure 3a while figure 3b illustrates ERPs after DHEA.   The 
ERPs shown in both figure 3a and figure 3b show the well-documented “old/new” 
effect (Wilding and Rugg 1996; McAllister-Williams and Rugg 2002).  In both 
figures, from around 400 ms post stimulus, the HH ERPs are more positive going than 
CR ERP.   
 
A priori, it was decided to quantify the ERP data by measuring, with respect to the 
mean of the pre-stimulus baseline, the mean amplitudes of four consecutive latency 
regions, 200-500, 500-800, 800-1100 and 1100-1400 ms post stimulus, as done 
previously (Wilding and Rugg 1996; McAllister-Williams and Rugg 2002).  ANOVA 
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was used to analyse data from all active 29 electrodes.  In addition, an ANOVA was 
conducted on four clusters of the electrodes, three each in the left anterior (FP1, F7 
and F3), right anterior (FP2, F8 and F4), left posterior (O1, P7 and P3) and right 
posterior quadrants (O2, P8 and P4) chosen priori on the basis of previous data 
demonstrating the “old/new” effect (Wilding and Rugg 1996; McAllister-Williams 
and Rugg 2002).  These analyses were conducted on the mean amplitudes of HH and 
CR waveforms for each of the four latency periods described above. 
 
Analysis of the all 29 active electrode sites revealed a significant effect of response 
(HH vs. CR) for both the 500-800 ms (1.7 vs. 1.07 µv; F(1,19)= 4.56 p<0.05) and 
1100-1400 ms (0.56 vs. 0.01 µv; F(1,19)= 5.49 p<0.05) latency regions (see figure 3a 
and 3b).  There was a significant effect of drug (DHEA vs. placebo) between 1100-
1400 ms (0.01 vs. 0.56 µv; F(1,19)= 5.49 p<0.05) and a trend for an effect between 
800-1100 ms (1.21 vs. 1.71 µv; F(1,19)= 3.19 p<0.1) post stimulus.  There was 
however, only a trend for an interaction between drug and response between in the 
200-500 ms and 800-1100 ms (p<0.1) latency regions. 
 
Analysis of the four quadrants found a significant response by location (i.e. anterior 
vs. posterior) interaction between 500 and 800 ms and 1100 and 1400 ms latency 
regions, due to the “old/new” effect being more positive posteriorly in the earlier 
periods and anteriorly in the later period.  This data is consistent with the late 
posterior negativity (LPN) slow wave previously identified in source memory tasks 
(reviewed by Johansson and Mecklinger 2003).  There was also a significant response 
by hemisphere (right vs. left) interaction between 1100 and 1400 ms due to the 
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“old/new” effect being more positive on the right, as described previously (Wilding 
and Rugg 1996; McAllister-Williams and Rugg 2002).  A main effect of drug was 
found between 1100 and 1400 ms with waveforms being more negative after DHEA 
(p<0.05).  However, there was no significant drug by response interaction, indicating 
that the effect of DHEA was independent of response type. 
 
The electrical source of activity recorded on the scalp related to episodic memory 
retrieval was examined with LORETA by comparing ERPs associated with HH and 
CR responses in the placebo condition.  Firstly, a TANOVA was conducted to 
identify time periods of statistical difference.  This revealed HH and CR related 
potentials to be consistently significantly different between 684 and 768 ms post-
stimulus (p<0.05 corrected for multiple comparisons).  Secondly, LORETA source 
localisation solutions for this time period for HH and CR related ERPs were 
statistically compared on a voxel-by-voxel basis.  As illustrated in figure 4a, 
LORETA images following placebo treatment demonstrated highly significant 
difference between HH and CR comparisons, which was maximal in the hippocampus 
in association with successful recollection between 684 and 768 ms post stimulus (t = 
5.04; p<0.001).  In a similar way following DHEA treatment, LORETA current 
density values associated with HH and CR showed that successful recollection was 
associated with maximal activation in the insula (t = 5.05  p<0.01), as shown in figure 
4b.  
 
To examine the effect of DHEA on the neural correlates of episodic recollection, 
mean amplitudes of ERPs associated with CR were sub
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with HH responses (HH-CR).  Subsequently, subtracted ERPs following DHEA and 
placebo were analysed using LORETA.  TANOVA revealed significant difference 
between topographic maps following DHEA and placebo between 380 and 438 ms 
post stimulus (p< 0.05).  Voxel-wise LORETA comparisons revealed a trend for an 
effect of DHEA treatment due to differentially higher activation of the anterior 
cingulated cortex (ACC) compared to placebo (p=0.06), as illustrated in figure 5. 
 
Discussion 
The most important findings of this study are the improvement of mood and memory 
and the possible differential activation of ACC in the episodic memory task following 
repeated oral administration of DHEA in healthy young men.  The study revealed that 
DHEA improved subjective ratings of mood in young healthy male subjects, which 
extends previous findings of mood improvement in elderly subjects and depressed 
patients (Wolkowitz et al. 1999; Wolf and Kirschbaum 1999).  The study also showed 
that DHEA improved memory both subjectively, as measured by VAS, and 
objectively as measured by episodic memory recollection.   
 
DHEA is being used in some countries, particularly the USA, by many people as an 
over-the-counter food supplement with unsupported recommendation of 50mg/day for 
men and 25mg/day for women, aiming to increase plasma concentrations of DHEA to 
those seen in young adults (Huppert and van Niekerk 2001).  Wide discrepancies have 
been found in previous studies investigating the effect of DHEA administration on 
memory in humans.  Since a continuous decline of DHEA concentrations occurs with 
ageing (Orentreich et al. 1984; Gray et al. 1991), most DHEA administration studies 
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have been conducted in the elderly using physiological doses.  In general, almost all 
previous studies investigating the effects of DHEA treatment on neurocognitive 
function have failed to show significant improvement or have been somewhat 
inconsistent in their findings.  In healthy elderly subjects, a two-week course of 
DHEA (50 mg/day) has been shown to cause a trend towards improvement in mood, 
well-being and visual memory in women but not men (Wolf et al. 1997).  A similar 
DHEA paradigm in elderly subjects under acute psychosocial stress showed DHEA 
(50 mg/day) treatment impaired declarative memory but improved attention (Wolf et 
al. 1998).  Longer durations of treatment (13-week course of DHEA, 50 mg/day) in a 
normal elderly population demonstrates association between high concentration of 
DHEA and less confusion, reduced anxiety and better mood; but DHEA has no 
significant benefits on cognition (van Niekerk et al. 2001).  Our study was different to 
these previous investigations of repeated DHEA administration due to our subjects 
being young healthy males.  To our knowledge, the only previous study to test the 
effects of DHEA on cognitive function in healthy young subjects used a single-dose 
of DHEA (300 mg) and found no effect on memory (Wolf et al. 1997).  In our study, 
we have used a similar relatively high (pharmacological) dose (150mg b.d.) over a 
one week period and demonstrated that this has beneficial effects on memory, 
suggesting that positive benefits of DHEA may require both pharmacological doses 
and repeated administration.   
 
DHEA treatment modified ERPs associated with episodic memory recollection and 
led to a possible differential activation of ACC between 380 and 438 ms post 
stimulus.  This early effect, if replicated, is of particular interest since ACC has been 
implicated in attention, executive function and memory processing (Morgane et al. 
Alhaj et al.                                          DHEA, episodic memory, cortisol and mood 
20/42 
2005).  The ACC has extensive connections with the hippocampus and it is possible 
that the differential activation of ACC following DHEA treatment may be due to pre-
hippocampal memory processing that enhanced successful recollection.  
 
To our knowledge, this is the first study to use LORETA source localisation of an 
episodic memory task.  In the placebo condition, episodic recollection was associated 
with activation of the hippocampus, which is recognised as playing an important role 
in many forms of memory.  However, following DHEA treatment, the site of maximal 
activation during recollection was another limbic structure, the insula. This has 
previously been shown in event-related fMRI studies to be activated during an 
episodic recollection task (Konishi et al. 2000).  The apparent difference in source 
localisation of episodic memory between placebo and DHEA pre-treatment conditions 
may simply reflect the low spatial resolution of LORETA.  This is supported by the 
fact that at the time these limbic structures were activated, there was no significant 
difference in the HH-CR subtracted ERP waveforms between DHEA and placebo 
treatments.  
 
It is difficult to determine the mechanisms of action of DHEA that led to beneficial 
effects on memory.  Data from animal studies have revealed that DHEA has a variety 
of actions on the central nervous system (CNS), including the promotion of 
neurogenesis in the hippocampal dentate gyrus, neuroprotection and reduction of 
neurodegeneration (Majewska 1995; Lapchak et al. 2000; Lapchak and Araujo 2001; 
Karishma and Herbert 2002).  DHEA also has effects on several neurotransmitter 
receptor systems known to impact on memory function.  For example, it acts as an 
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agonist at glutamate NMDA receptors and it is known that NMDA receptor 
antagonists impair memory (Wolf and Kirschbaum 1999).  Furthermore, DHEA 
shows functional antagonistic properties at GABAA receptors and agonistic properties 
at sigma receptors (Majewska 1992; Monnet et al. 1995) with many studies 
demonstrating that both GABAA antagonists and sigma agonists may enhance 
memory (Wolf and Kirschbaum 1999).  DHEA is a precursor of oestrogens and 
androgens, and so it is also possible that memory improvement with DHEA was, in 
part, due effects of sex steroids on cognition (Hirshman et al. 2004).  An increase in 
gonadal steroids has been shown in previous studies following DHEA administration 
(Morales et al. 1994; Morales et al. 1998).  Memory-enhancing effects of gonadal 
steroids have also been frequently reported following administration of oestradiol 
(Phillips and Sherwin 1992; Hogervorst et al. 2000) and testosterone (Cherrier et al. 
2001; Aleman et al. 2004).  Since the present study did not measure plasma 
concentrations of testosterone and oestradiol it is not possible to comment on whether 
the observed effects of DHEA were in fact medicated following its conversion to 
these cannot be decided whether these steroids led, or at least contributed to the effect 
of DHEA seen in the current study. 
 
The finding of a beneficial effect of DHEA on mood is necessarily speculative since 
only a subjective rating scale was used in this study.  However, this effect may have 
resulted from DHEA reported ability to modulate 5-HT systems; for example 
enhancing the firing rate of 5-HT neurons (Robichaud and Debonnel 2004).  
Improvement in mood has been noted in depressed patients following treatment with 
DHEA (Wolkowitz et al. 1999), although other studies have found no improvements 
in perimenopausal mood symptoms (Barnhart et al. 1999). 
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Findings from this study demonstrate that repeated administration of DHEA produces 
long-lasting elevation of salivary DHEA concentrations and possibly a decrease of 
evening salivary cortisol concentrations, though since this was only shown with a 
post-hoc t-test, the finding needs to be replicated.  In a placebo controlled study, Wolf 
and colleagues (1997) found that a single dose of DHEA led to an immediate decrease 
in cortisol concentrations.  Interestingly, in that study DHEA was administered during 
the evening, i.e. during the cortisol trough.  Our results reveal that repeated DHEA 
treatment does not change morning cortisol concentrations and the decrease in 
evening cortisol concentrations does not appear to simply be due to the acute effect of 
DHEA administration since the largest effect was seen immediately prior to taking the 
evening dose.  If confirmed, these findings may be of great interest since trough 
cortisol concentrations in particular are elevated in depression (Young et al. 1994).  A 
reverse of this may underlie the reported benefits of DHEA in depression (Wolkowitz 
et al. 1999).   
 
The potential therapeutic implications of these findings need to be considered with 
considerable caution.  Firstly, it is difficult to extrapolate the current positive effects 
of DHEA on memory and mood from this study in young healthy individuals to an 
elderly population with memory impairments.  The current study investigated the 
effects of supraphysiological doses in a population with high baseline endogenous 
DHEA concentrations. It is unclear what dose would be required to produce similar 
effects, if these are possible, in a population with lower baseline DHEA 
concentrations. Secondly, the use of such high doses of DHEA as used here over the 
long term, could theoretically lead, via metabolism into active sex steroids, to adverse 
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effects, such as enhanced hormone-sensitive tumour growth (Wolkowitz et al. 2003).  
As a result future investigations need to proceed with caution.  This is despite a report 
that DHEA administration at pharmacological (but not physiological) concentrations 
inhibits angiogenesis, which is implicated in the pathologies of neoplasm, both in 
vitro and in vivo (Varet et al. 2004). 
 
In summary, this study has shown that DHEA treatment led to enhancement in 
recollection accuracy associated with a modification in the electrophysiological 
correlates of episodic memory retrieval.   In addition, DHEA improved subjective 
memory and mood, and decreased evening cortisol concentrations.  These unique 
findings are the first to show such beneficial effects of DHEA in healthy young males.   
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Table1. The mean ± standard deviation of visual analogue scale measures following DHEA and 
placebo (in mm.). DHEA improved subjective mood and memory (*= p<0.05) but had no effect on the 
other VASs. Note that the larger the number, the better the subjective rating of each variable. 
 
 Placebo DHEA 
Mood * 71.9 ±16.2 78.9±10.6  
Memory * 71±14.2 76±14.6 
Sexual Drive 74.8±17.3 77.4±16.6 
Appetite 71.1±19.5 74.4±16.3 
Alertness 70.9±16.1 69.1±10.8 
Well-being 75.7±18.1 77.3±12.7 
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FIGURE LEGENDS 
Fig. 1 A. Salivary DHEA concentrations following DHEA (solid line) and placebo (dashed line). 
Concentrations were measured on day 7 and day 8 of treatment. Arrows show time of last two 
treatment administration.  B. Salivary cortisol concentrations following DHEA (solid line) and placebo 
(dashed line). All other details are as described for Fig. 1A 
 
Fig. 2 Episodic memory performance following DHEA and placebo treatments A. Memory recognition 
i indexed by the probability of a correct recognition of an old item (H) minus the probability of falsely 
referring to a new item as old (FA); see text for details. B. Episodic memory recollected as 
demonstrated by pHH/H (probability of accurate recollection given recognition of an old item; see text 
for details) 
 
Fig.  3 Grand average ERP waveforms from representative electrode sites: F4 (right anterior), F3 (left 
anterior), P4 (right posterior) P3 (left posterior).  CR related ERPs are shown with a solid line, while 
HH related ERPs are shown with a dashed line.  A. CR and HH related ERP grand averages following 
placebo administration. B. CR and HH related ERP grand averages following DHEA administration.  
 
Fig. 4 Statistical nonparametric LORETA maps of activation during recollection as assessed by the 
comparison of HH with CR responses.  (L=left; R=right; A=anterior; P=posterior).  A. LORETA 
localisation of HH vs. CR responses following placebo administration.  Maximal activation is in the 
hippocampus (p<0.001)  B. LORETA localisation of HH vs. CR following DHEA administration.  
Maximal activation is in Broadman Area 13 (Insula, Sub-lobar p<0.01) 
 
Fig. 5 LORETA localisation of subtraction ERP waveforms (HH-CR) following DHEA and placebo 
administration between 380 and 438 ms post stimulus.  Maximal activation is seen in Broadman Area 
25 (Anterior Cingulate, Limbic Lobe p=0.06) 
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Figure 1. 
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Figure 2 
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Figure 3. 
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Figure 4. 
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Figure 5. 
 
 
